MIRA Pharmaceuticals, Inc.
MIRAMIRA Pharmaceuticals reported a net loss of $10.4 million for fiscal year 2025, reflecting the capital-intensive nature of advancing its clinical-stage neuroscience pipeline.
NASDAQ
Healthcare
Drug Manufacturers - General
$1.10
+0.04(4.2%)
52W $0.80 – $2.02
AI-generated
MIRA Pharmaceuticals reported a net loss of $10.4 million for fiscal year 2025, reflecting the capital-intensive nature of advancing its clinical-stage neuroscience pipeline.
$46MMkt Cap
—Rev TTM
-$62MNI TTM
-0.8xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 30, 2026MIRA Pharmaceuticals reported a net loss of $10.4 million for fiscal year 2025, reflecting the capital-intensive nature of advancing its clinical-stage neuroscience pipeline. Operating cash usage of $4.7 million underscores the company's focus on development activities, with current resources expected to fund operations into at least the first quarter of 2027.
What Changed Recently
Fundamentals
How The Business Makes Money
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Industry Drug Manufacturers - General
Analyst View
Company Profile
CIK0001904286
ISINUS60458C1045
CUSIP60458C104
Phone737-289-0835
Address855 North Wolfe Street, Baltimore, MD, 21205, US
SEC EDGAR